Exclusive extracts from this 25-page-long report:
- Who is the player?
Bayer was created in 1863 and, over time, has evolved from a diversified chemicals groups into a life science company with a focus on pharmaceuticals, health and agriculture. Bayer has fine-tuned its portfolio in recent years, increasing its presence in consumer health by adding the OTC businesses of US-based Merck and Dihon of China in 2014. [...]
- What are the player's strategies?
In September 2017, Bayer officially ceded control of its former MaterialScience division, Covestro, reaching an important milestone in its transformation into a Life Science company. The divestment has generated significant revenues (>€9bn since Covestro's IPO in 2015), partly due to Covestro's higher than expected share price performance, and this was largely responsible for the company's exceptional annual 2017 net income figure (€7.3bn; >60% increase). […]
- What are the player's strengths and weaknesses?
A global life science leader
Geographical diversification reduces exposure to one region
Solid R&D pipeline […]
Numerous lawsuits pending against several medications (€124m in charges in 2017)
Product dependency: 5 drugs accounted for almost 40% of Pharmaceuticals sales in 2017 […]
- What is the player's financial position?
The financial indicators included in the report include: Consolidated net revenues, Consolidated operating income and margin, Number of employees in R&D, R&D expenses, Sales by segment, Sales performance by segment, Sales by region, Sales performance by region, Profitability ratios, Liquidity ratios, Solvency ratios and Free cash flow and capital expenditure.